Please wait
Healthcare · Diagnostics & Research · Price, fundamentals, signals, and forward-looking context in one research view.
Healthcare
$32.6B
N/A
42.52
Current price
$213.63
-0.9% todayUpdated 11 min ago
Open
$224.73
Previous close
$215.59
Day range
$208.98 – $225.10
Volume
N/A
42.5x P/E
Awaiting filing
No current yield
65/100 measured
Easy to trade
Recent price movement, key market context and the latest company information.
The latest saved price history for ILMN, with its range and direction at a glance.
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Investors usually follow ILMN for its valuation signal, sector position, and upcoming company events. The goal here is not just to show numbers, but to explain what they mean in plain English.
Whisone is bullish because fundamentals are solid at 75/100 while there is no strong bear warning from the current data. Whisone has high conviction here. The final read is being balanced by the weighted scores for fundamentals, technicals, insider flow, sentiment, event flow, and liquidity.
Whisone v2 splits the read into weighted parts so the score is not just one hidden number.
Fundamentals
Growth, margins, cash flow, and valuation.
Latest net profit
$134M
TTM (2026-06-30)
ROE
32.3%
Return on equity
ROA
8.7%
Return on assets
Debt / equity
0.95
Lower is usually safer.
P/B ratio
11.47
Useful for book value support.
85/100
Direction
Range-bound
Main supports
Business quality and balance-sheet strength are supporting the outlook.
Recent price behavior and momentum still support follow-through.
Recent price and fundamentals refreshes improve signal reliability.
What can go wrong
Volatility is elevated, so the path can stay rough even if the thesis is right.
Analyst target data does not currently point to clear upside.
Fair value
$207.24
Analyst view
Buy
Analyst target
$198.89
Forecast refresh
Updated just now
Quality score
73
Growth score
50
These are the external analyst numbers and business outlook figures already synced into the company record.
No external analyst outlook is available for this company yet.
A plain-English reading of momentum, trend, volatility, range position, and trading participation.
RSI
N/A
Momentum data is not available yet.
Recent trend
Rising
+4.2% across the latest saved price window.
Volatility
High
Beta is 1.46. Price may swing more than the wider market.
52-week position
87% of range
Price is trading close to its 52-week high.
Volume confirmation
N/A
Comparable volume data is not available.
PMG-MAN stated the pharmaceutical sector spends a large share of revenue on energy, reducing competitiveness industry-wide.
policy_stability_and_support
ILMN may also move because the HEALTHCARE sector may benefit from policy_stability_and_support. Confidence 60%.
The sector would benefit from extended Presidential Executive Order, dedicated energy tariffs, and policies encouraging local API production to attract investment and boost local manufacturing.
ILMN
Illumina, Inc.
Price: $213.63
P/E: 42.522682
Yield: N/A
ABBV
AbbVie Inc.
Price: $256.42
P/E: 72.994286
Yield: 2.7%
ABT
Abbott Laboratories
Price: $110.36
P/E: 36.39806
Yield: 2.3%
ALGN
Align Technology, Inc.
Price: $159.79
P/E: 27.310226
Yield: 0.0%
Industry
Diagnostics & Research
Employees
8600
Exchange
NMS
Ticker
ILMN
